BioNTech (BNTX) is trading higher today as investors react to a fresh oncology catalyst dated April 11, 2026: positive Phase 2 results for trastuzumab pamirtecan in HER2-expressing, recurrent endometrial cancer. The update reported a confirmed objective response rate (ORR) of 47.9% in centrally tested patients (n=145), along with a median progression-free survival (mPFS) of 8.1 months and a median duration of response (DoR) of 10.3 months—metrics that suggest meaningful anti-tumor activity in a difficult-to-treat setting.

With COVID-related revenues structurally lower than the pandemic peak, BioNTech’s equity story has increasingly hinged on its ability to convert a deep oncology pipeline into late-stage assets with a clear path to approval and commercial scale. A response rate near 50% and a double-digit median DoR can be interpreted by the market as a signal that the antibody-drug conjugate program could become one of the nearer-term value drivers, particularly if BioNTech can outline next steps toward a registrational strategy.

Key follow-ups for traders include whether BioNTech provides additional detail on safety/tolerability, subgroups, and confirmatory plans, and whether it signals discussions with regulators on trial design that could support an approval filing. Investors will also be looking for the next set of oncology catalysts in 2026 that can reinforce momentum across BioNTech’s late-stage portfolio beyond its COVID franchise.